(REGN) Regeneron Pharmaceuticals - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US75886F1075
Stock: Eye Disease, Asthma, Cancer, Arthritis
Total Rating 56
Risk 97
Buy Signal 0.14
| Risk 5d forecast | |
|---|---|
| Volatility | 36.3% |
| Relative Tail Risk | -4.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.37 |
| Alpha | -1.82 |
| Character TTM | |
|---|---|
| Beta | 0.651 |
| Beta Downside | 0.427 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.69% |
| CAGR/Max DD | 0.03 |
EPS (Earnings per Share)
Revenue
Description: REGN Regeneron Pharmaceuticals March 05, 2026
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that develops and commercializes medicines for various diseases.
The companys product portfolio includes treatments for eye conditions, inflammatory diseases, cardiovascular issues, and cancer. Biotechnology companies typically invest heavily in research and development, with a long product development cycle.
REGN has strategic collaborations with other pharmaceutical companies, including Bayer and Alnylam Pharmaceuticals, for drug development and commercialization. These partnerships are common in the pharmaceutical sector to share development costs and expand market reach.
For more detailed financial analysis, ValueRay offers comprehensive insights.
Headlines to watch out for
- EYLEA sales growth drives revenue stability
- Dupixent expansion boosts immunology portfolio
- Pipeline success critical for future growth
- Regulatory approvals impact drug commercialization
- Competition from biosimilars pressures EYLEA market share
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 4.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.53 > 1.0 |
| NWC/Revenue: 95.19% < 20% (prev 103.6%; Δ -8.43% < -1%) |
| CFO/TA 0.12 > 3% & CFO 4.98b > Net Income 4.50b |
| Net Debt (-412.2m) to EBITDA (5.82b): -0.07 < 3 |
| Current Ratio: 4.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.5m) vs 12m ago -5.54% < -2% |
| Gross Margin: 85.35% > 18% (prev 0.86%; Δ 8449 % > 0.5%) |
| Asset Turnover: 36.63% > 50% (prev 37.61%; Δ -0.98% > 0%) |
| Interest Coverage Ratio: 120.4 > 6 (EBITDA TTM 5.82b / Interest Expense TTM 43.8m) |
Altman Z'' 10.00
| A: 0.34 (Total Current Assets 18.02b - Total Current Liabilities 4.37b) / Total Assets 40.56b |
| B: 0.88 (Retained Earnings 35.80b / Total Assets 40.56b) |
| C: 0.13 (EBIT TTM 5.27b / Avg Total Assets 39.16b) |
| D: 3.86 (Book Value of Equity 35.87b / Total Liabilities 9.30b) |
| Altman-Z'' Score: 10.04 = AAA |
Beneish M -3.02
| DSRI: 0.92 (Receivables 5.74b/6.21b, Revenue 14.34b/14.20b) |
| GMI: 1.01 (GM 85.35% / 86.13%) |
| AQI: 1.12 (AQ_t 0.43 / AQ_t-1 0.38) |
| SGI: 1.01 (Revenue 14.34b / 14.20b) |
| TATA: -0.01 (NI 4.50b - CFO 4.98b) / TA 40.56b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of REGN shares?
As of March 10, 2026, the stock is trading at USD 781.60 with a total of 697,058 shares traded.
Over the past week, the price has changed by -1.16%, over one month by +0.29%, over three months by +12.99% and over the past year by +5.51%.
Over the past week, the price has changed by -1.16%, over one month by +0.29%, over three months by +12.99% and over the past year by +5.51%.
Is REGN a buy, sell or hold?
Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28.
Therefore, it is recommended to buy REGN.
- StrongBuy: 14
- Buy: 5
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the REGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 872.7 | 11.7% |
| Analysts Target Price | 872.7 | 11.7% |
REGN Fundamental Data Overview March 07, 2026
P/E Trailing = 18.4498
P/E Forward = 18.3486
P/S = 5.6382
P/B = 2.6636
P/EG = 1.6839
Revenue TTM = 14.34b USD
EBIT TTM = 5.27b USD
EBITDA TTM = 5.82b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = 37.8m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -412.2m USD (from netDebt column, last quarter)
Enterprise Value = 74.97b USD (80.87b + Debt 2.71b - CCE 8.61b)
Interest Coverage Ratio = 120.4 (Ebit TTM 5.27b / Interest Expense TTM 43.8m)
EV/FCF = 18.37x (Enterprise Value 74.97b / FCF TTM 4.08b)
FCF Yield = 5.44% (FCF TTM 4.08b / Enterprise Value 74.97b)
FCF Margin = 28.45% (FCF TTM 4.08b / Revenue TTM 14.34b)
Net Margin = 31.41% (Net Income TTM 4.50b / Revenue TTM 14.34b)
Gross Margin = 85.35% ((Revenue TTM 14.34b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 84.95% (prev 86.11%)
Tobins Q-Ratio = 1.85 (Enterprise Value 74.97b / Total Assets 40.56b)
Interest Expense / Debt = 0.45% (Interest Expense 12.2m / Debt 2.71b)
Taxrate = 19.08% (199.1m / 1.04b)
NOPAT = 4.27b (EBIT 5.27b * (1 - 19.08%))
Current Ratio = 4.13 (Total Current Assets 18.02b / Total Current Liabilities 4.37b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 31.26b)
Debt / EBITDA = -0.07 (Net Debt -412.2m / EBITDA 5.82b)
Debt / FCF = -0.10 (Net Debt -412.2m / FCF TTM 4.08b)
Total Stockholder Equity = 30.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.50% (Net Income 4.50b / Total Assets 40.56b)
RoE = 14.83% (Net Income TTM 4.50b / Total Stockholder Equity 30.39b)
RoCE = 16.29% (EBIT 5.27b / Capital Employed (Equity 30.39b + L.T.Debt 1.99b))
RoIC = 13.19% (NOPAT 4.27b / Invested Capital 32.37b)
WACC = 8.06% (E(80.87b)/V(83.57b) * Re(8.32%) + D(2.71b)/V(83.57b) * Rd(0.45%) * (1-Tc(0.19)))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.81%
[DCF] Terminal Value 76.34% ; FCFF base≈3.89b ; Y1≈3.53b ; Y5≈3.07b
[DCF] Fair Price = 528.0 (EV 54.45b - Net Debt -412.2m = Equity 54.86b / Shares 103.9m; r=8.06% [WACC]; 5y FCF grow -11.54% → 2.90% )
EPS Correlation: 30.97 | EPS CAGR: 6.83% | SUE: 0.59 | # QB: 0
Revenue Correlation: 77.36 | Revenue CAGR: 7.47% | SUE: 0.52 | # QB: 0
EPS next Quarter (2026-06-30): EPS=10.69 | Chg7d=+0.025 | Chg30d=+0.024 | Revisions Net=-5 | Analysts=22
EPS current Year (2026-12-31): EPS=44.83 | Chg7d=+0.148 | Chg30d=+0.278 | Revisions Net=+2 | Growth EPS=+1.2% | Growth Revenue=+9.0%
EPS next Year (2027-12-31): EPS=46.91 | Chg7d=+0.000 | Chg30d=+0.478 | Revisions Net=+1 | Growth EPS=+18.8% | Growth Revenue=+10.1%
[Analyst] Revisions Ratio: -0.45 (3 Up / 8 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.9% (Discount Rate 8.3% - Earnings Yield 5.4%)
[Growth] Growth Spread = +0.6% (Analyst 3.5% - Implied 2.9%)
P/E Forward = 18.3486
P/S = 5.6382
P/B = 2.6636
P/EG = 1.6839
Revenue TTM = 14.34b USD
EBIT TTM = 5.27b USD
EBITDA TTM = 5.82b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = 37.8m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -412.2m USD (from netDebt column, last quarter)
Enterprise Value = 74.97b USD (80.87b + Debt 2.71b - CCE 8.61b)
Interest Coverage Ratio = 120.4 (Ebit TTM 5.27b / Interest Expense TTM 43.8m)
EV/FCF = 18.37x (Enterprise Value 74.97b / FCF TTM 4.08b)
FCF Yield = 5.44% (FCF TTM 4.08b / Enterprise Value 74.97b)
FCF Margin = 28.45% (FCF TTM 4.08b / Revenue TTM 14.34b)
Net Margin = 31.41% (Net Income TTM 4.50b / Revenue TTM 14.34b)
Gross Margin = 85.35% ((Revenue TTM 14.34b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 84.95% (prev 86.11%)
Tobins Q-Ratio = 1.85 (Enterprise Value 74.97b / Total Assets 40.56b)
Interest Expense / Debt = 0.45% (Interest Expense 12.2m / Debt 2.71b)
Taxrate = 19.08% (199.1m / 1.04b)
NOPAT = 4.27b (EBIT 5.27b * (1 - 19.08%))
Current Ratio = 4.13 (Total Current Assets 18.02b / Total Current Liabilities 4.37b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 31.26b)
Debt / EBITDA = -0.07 (Net Debt -412.2m / EBITDA 5.82b)
Debt / FCF = -0.10 (Net Debt -412.2m / FCF TTM 4.08b)
Total Stockholder Equity = 30.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.50% (Net Income 4.50b / Total Assets 40.56b)
RoE = 14.83% (Net Income TTM 4.50b / Total Stockholder Equity 30.39b)
RoCE = 16.29% (EBIT 5.27b / Capital Employed (Equity 30.39b + L.T.Debt 1.99b))
RoIC = 13.19% (NOPAT 4.27b / Invested Capital 32.37b)
WACC = 8.06% (E(80.87b)/V(83.57b) * Re(8.32%) + D(2.71b)/V(83.57b) * Rd(0.45%) * (1-Tc(0.19)))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.81%
[DCF] Terminal Value 76.34% ; FCFF base≈3.89b ; Y1≈3.53b ; Y5≈3.07b
[DCF] Fair Price = 528.0 (EV 54.45b - Net Debt -412.2m = Equity 54.86b / Shares 103.9m; r=8.06% [WACC]; 5y FCF grow -11.54% → 2.90% )
EPS Correlation: 30.97 | EPS CAGR: 6.83% | SUE: 0.59 | # QB: 0
Revenue Correlation: 77.36 | Revenue CAGR: 7.47% | SUE: 0.52 | # QB: 0
EPS next Quarter (2026-06-30): EPS=10.69 | Chg7d=+0.025 | Chg30d=+0.024 | Revisions Net=-5 | Analysts=22
EPS current Year (2026-12-31): EPS=44.83 | Chg7d=+0.148 | Chg30d=+0.278 | Revisions Net=+2 | Growth EPS=+1.2% | Growth Revenue=+9.0%
EPS next Year (2027-12-31): EPS=46.91 | Chg7d=+0.000 | Chg30d=+0.478 | Revisions Net=+1 | Growth EPS=+18.8% | Growth Revenue=+10.1%
[Analyst] Revisions Ratio: -0.45 (3 Up / 8 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.9% (Discount Rate 8.3% - Earnings Yield 5.4%)
[Growth] Growth Spread = +0.6% (Analyst 3.5% - Implied 2.9%)